Parkinson's vaccine – clinical results boost prospects

September 7, 2016

AFFiRiS AG announced today results of AFF008A, a Phase I clinical trial to assess boost immunizations with AFFITOPE PD01A, an active vaccine against Parkinson's disease (PD). The study was funded by a $1.04 million grant from The Michael J. Fox Foundation for Parkinson's Research.

The "boost" study AFF008A was designed to assess one boost immunization with AFFITOPE PD01A per patient with regard to safety/tolerability and immunological and clinical activity in those who had already received the vaccine (four "priming" vaccinations at four-week intervals) within the first-in-man clinical study AFF008. Six PD patients on best medical care, including standard symptomatic medication, served as a comparison group. In the "boost" study, two different doses of AFFITOPE PD01A (15 µg and 75 µg) were again safe and well tolerated, meeting the primary endpoint of the trial.

Patients belonging to the low-dose group of AFF008 were randomized in two equally distributed groups receiving either 15 µg or 75 µg AFFITOPE PD01A. The same was done with patients of the AFF008 high-dose group, in order to allow for evaluation of four different vaccination schedules.

Across all patients, no antibody concentration limiting toxicity was observed. Adverse events were similar across all five groups except injection site reactions, which only occurred in the active treatment groups, and psychiatric disorders, reported at a lower rate in the active groups. All of the 28 patients completed the study and received all planned vaccinations. Only one serious adverse event was reported, which was classified as being not related to AFFITOPE PD01A administration.

An immune response against AFFITOPE PD01A was seen in 19 of 22 (86%) of vaccinated patients and 12 of 19 (63%) of these responders generated aSyn-specific serum antibodies. The immune response sustained throughout the entire observation period of 24 weeks. Patients on low dose and then high dose had a clear immunological boost. This data supports that further dose and scheduling may significantly influence antibody titer/concentration and further studies need to be performed. Additionally, vaccine-induced antibodies were detectable in cerebrospinal fluid. This induction of antibodies against aSyn supports the concept of the principle of AFFiRiS' proprietary therapeutic vaccine.

Parallel laboratory experiments using recombinant aSyn protein to assess selectivity showed that AFFITOPE PD01A-induced antibodies preferentially bind to aSyn fibrils, which are believed to be the toxic form of the protein, as compared to the monomeric form.

Due to the limitations of the Phase I trial design (the study was not double-blind, and assignment to the comparison group was not randomized), it is not known whether effects seen in the active groups are indicative of treatment effects or due to confounding factors. Efficacy variables were evaluated in an explorative manner with regard to the small sample size. Preliminary observations showed that in eight of the 19 (42%) immunological responders, no increase of the concomitant dopaminergic PD medication was needed throughout the observational period (on average three years per subject). Among the same group, five of eight (63%) patients had stable UPDRS III scores at the end of the "boost" study.

Continuous efforts are undertaken to follow this patient cohort and to further characterize their immunological and clinical response to treatment with AFFITOPE PD01A. The next study, AFF008AA, is focusing primarily on the long-term safety and, in addition, on the assessment of the immunological and clinical effects of a second boost vaccination ("reboost"). That study is also funded by The Michael J. Fox Foundation, as was the AFF008 trial. Recruitment of patients for AFF008AA has been completed; results are expected in Q2 2017.

Explore further: First clinical data of therapeutic Parkinson's disease vaccine encourages continued development

Related Stories

First clinical data of therapeutic Parkinson's disease vaccine encourages continued development

August 1, 2014
AFFiRiS AG announced today at a press conference in New York results of AFF008, a Phase I clinical trial of PD01A, a vaccine against Parkinson's disease. PD01A is the first therapy against the protein alpha-synuclein, a promising ...

EU team launches clinical trial of Parkinson's vaccine

December 9, 2014
Today the EU-consortium SYMPATH starts recruitment for a Phase I study of a Parkinson's vaccine candidate called AFFITOPE PD03A. This vaccine is one out of a designated pool of promising vaccine candidates based on AFFiRiS' ...

Study examines safety, immune response of candidate Ebola vaccines

April 19, 2016
In a study appearing in the April 19, 2016 issue of JAMA, Matthew D. Snape, F.R.C.P.C.H., M.D., of the University of Oxford, United Kingdom, and colleagues conducted a phase 1 trial to evaluate the tolerability and immunogenicity ...

Leading chikungunya vaccine in clinical trial phase 2

August 26, 2016
With the first patient vaccinated, a phase 2 clinical trial of a promising prophylactic vaccine candidate against Chikungunya fever has now commenced. The product is the most advanced Chikungunya vaccine candidate globally ...

Study finds HPV vaccine protects children with vulnerable immune systems

July 20, 2016
While the protective benefits of the HPV vaccine in the general population are well known, new research shows it may also benefit children with weakened immune systems who are at higher risk of HPV-related cancers. The research, ...

NIH begins testing investigational Zika vaccine in humans

August 3, 2016
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched a clinical trial of a vaccine candidate intended to prevent Zika virus infection. The early-stage ...

Recommended for you

Singing may be good medicine for Parkinson's patients

August 11, 2017
(HealthDay)—Singing? To benefit people with Parkinson's disease? It just may help, a researcher says.

Tracing the path of Parkinson's disease proteins

August 4, 2017
As neurodegenerative disorders such as Parkinson's and Alzheimer's disease progress, misfolded proteins clump together in neurons, recruiting normal proteins in the cell to also misfold and aggregate. Cells in which this ...

Diabetes drug shows potential as disease-modifying therapy for Parkinson's disease

August 3, 2017
A drug commonly used to treat diabetes may have disease-modifying potential to treat Parkinson's disease, a new UCL-led study suggests, paving the way for further research to define its efficacy and safety.

Two new studies offer insights into gastrointestinal dysfunction in Parkinson's patients

July 31, 2017
Constipation is one of the most common non-motor related complaints affecting Parkinson's disease (PD) patients. Two important studies from the same research group published in the Journal of Parkinson's Disease expand the ...

New drug may treat and limit progression of Parkinson's disease

July 31, 2017
Researchers at Binghamton University have developed a new drug that may limit the progression of Parkinson's disease while providing better symptom relief to potentially hundreds of thousands of people with the disease.

A new insight into Parkinson's disease protein

July 28, 2017
Abnormal clumps of certain proteins in the brain are a prominent feature of Parkinson's and other neurodegenerative diseases, but the role those same proteins might play in the normal brain has been unknown.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.